

ENDOGENOUS SERUM TESTOSTERONE IN MAN: AGEING, THE METABOLIC SYNDROME, FUNCTIONAL DECLINE AND THE ROLE OF SUPPLEMENTATION

Matthew Timothy Haren

B.App.Sc (Human Movement), B.Health.Sc(Hons)

Departments of Medicine and Public Health

Faculty of Health Sciences

The University of Adelaide

Adelaide, South Australia

Australia

Thesis submitted in total fulfillment of the Degree of Doctor of Philosophy (PhD)

February 2005



In memory of my dear old dad Tim

And

For my mum Pat and sisters Marie-Ann and Carmel

Table of Contents

ACKNOWLEDGEMENTS	xxxvii
STATEMENT OF ORIGINALITY AND AUTHENTICITY	xli
TABLE OF ABBREVIATIONS AND BIOCHEMICAL NAMES	xlii
PAPERS ARISING FROM THIS THESIS	i
SUMMARY	li
CHAPTER 1.0 INTRODUCTION	1
SUMMARY	1
ENDOGENOUS SERUM TESTOSTERONE IN MAN: REGULATION, PHYSIOLOGY, EFFECT OF AGEING AND DISEASE, AND THE ROLE OF SUPPLEMENTATION	2
Androgen biosynthesis and metabolism.....	2
The measurement of testosterone in serum.....	4
Physiological function of androgens in ageing men	5
The associations between ageing and the various measures of plasma testosterone	44
Associations between androgen levels and health in ageing men	46
Symptoms of androgen deficiency, mood, psychosexual function and quality of life	46

Cognitive function - spatial ability.....	47
Body composition and muscle strength	47
Bone mineral density	47
Plasma lipids.....	48
Prostate	49
The problem of defining relative (or partial) androgen deficiency.....	49
Screening for relative (or partial) androgen deficiency	50
Benefits and risks of androgen supplementation in ageing men.....	52
GENERAL HYPOTHESIS	75
SPECIFIC HYPOTHESES	75
SIGNIFICANCE OF PROJECT	76
Proposed studies.....	76
CHAPTER 2.0 COMMON METHODOLOGIES	78
SUMMARY	78
INTRODUCTION	78
Ethical approvals and safety considerations.....	78

Study Environment	79
Physical Measurements	79
Blood Pressure	79
Anthropometry	79
Urological Assessment.....	80
Neuropsychological Assessment	80
Muscle Function.....	81
Body composition.....	81
Laboratory Assays.....	82
Plasma total testosterone (Total T)	82
Sex hormone-binding globulin (SHBG)	82
Bioavailable testosterone (BT)	82
Calculated bioavailable (cBT) and free testosterone (cFT)	83
Follicle stimulating hormone (FSH), Lutenising hormone (LH), Oestradiol (E ₂).....	83
Lipid and glucose metabolism.....	83
Glyclated Haemoglobin (HbA1c).....	83

Prostate specific antigen (PSA).....	84
CHAPTER 3.0 THE MEASUREMENT AND CALCULATION OF BIOAVAILABLE TESTOSTERONE IN PLASMA	85
SUMMARY	85
INTRODUCTION	86
MATERIALS AND METHODS.....	87
Ammonium sulphate precipitation procedure	87
Blood products for assay development.....	87
Standard plasma.....	88
Quality control plasma	88
Testosterone tracer.....	88
Saturated ammonium sulphate.....	88
Assay protocol	89
Development of an equation for calculating BT (cBT)	89
Subjects.....	89
Measurements	90
Statistical Analysis	91

RESULTS.....	91
Quality control	91
Variation and reproducibility.....	91
Age-specific references ranges for assayed BT.....	92
Kd of the testosterone-SHBG complex	94
Calculation of BT.....	94
Age-specific reference ranges for cBT	97
Relationships of cBT, BT, FT and total T with muscle strength and QoL	97
DISCUSSION.....	100
CHAPTER 4.0 THE FLOREY ADELAIDE MALE AGEING STUDY (FAMAS): PROTOCOL AND CHARACTERISATION OF THE COHORT.....	103
SUMMARY.....	103
INTRODUCTION.....	104
METHODS.....	106
RECRUITMENT OF PARTICIPANTS.....	106
Selection and exclusion criteria	109
Study Plan and design	109

Questionnaires.....	111
Physical and mental health.....	111
Physical activity.....	114
Nutrient intake.....	114
Sexual function.....	115
Obstructive sleep apnoea.....	116
Direct measurements.....	116
Neuropsychology.....	116
Laboratory measurements.....	118
Communication of personal results.....	118
Data management, cleaning and coding procedures.....	119
Statistical analyses.....	123
Power calculations for testosterone effect.....	123
RESULTS.....	126
Participation and response rates.....	126
Demographics and health of negative responders compared to study participants.....	129

Demographics of recruited cohort	134
Age	134
Regional distribution	134
Marital status	134
Gross annual household income	135
Aboriginality	135
Country of birth and immigration year	135
Education level	144
Work status.....	144
DSS pension.....	144
Health indicators.....	150
Blood pressure.....	150
Body mass index and waist circumference	156
Cigarette smoking	162
Physical activity.....	162
Participation.....	162

Time spent in physical activity	162
Sufficient physical activity to confer a health benefit.....	163
Nutrient Intake.....	177
Distribution of total energy intake.....	177
Physical and mental health	185
Physical functioning (PF)	185
Role physical (RP)	185
Bodily pain (BP)	185
General health (GH)	186
Vitality (VT)	186
Role emotional (RE)	186
Mental health (MH)	186
Social functioning (SF).....	187
Laboratory.....	198
Fasting serum lipids.....	198
Fasting serum glucose and HbA1c	198

Self-reported health conditions	211
Psychological illness.....	211
Benign prostate disease, prostate cancer & urogenital surgery.....	211
Sleep Apnoea	211
Medication use	217
DISCUSSION	219
Response rates.....	219
Negative versus positive responders	221
Demographic characteristics of the cohort	222
Health characteristics of the cohort.....	222
CHAPTER 5.....	225
5.1 THE ASSOCIATIONS OF TOTAL, BIOAVAILABLE AND FREE TESTOSTERONE AND SHBG WITH SOCIO-DEMOGRAPHICS, DISEASE RISK FACTORS AND BEHAVIOURS, CHRONIC DISEASE AND MEDICATION USE.....	225
SUMMARY	225
INTRODUCTION	226
MATERIALS AND METHODS.....	229

Participant selection	229
Measurements	229
Statistical analysis.....	229
RESULTS.....	231
Demographics.....	231
Pituitary Hormones.....	234
Chronic disease risk factors and behaviours.....	234
Blood pressure.....	234
Waist circumference	234
Serum lipids.....	238
Dietary total energy and macronutrient intake	238
Glucose metabolism	238
Daily alcohol intake.....	238
Physical activity	243
Smoking.....	243
Chronic disease, surgical procedures and medications.....	243

Multivariate predictive models for serum testosterone and SHBG concentrations	249
Total testosterone	249
Bioavailable testosterone	249
Calculated bioavailable testosterone	249
Free testosterone	250
Sex hormone binding globulin	250
Do the significantly associated factors predict low testosterone levels?	259
Discriminators of BT < 3.1 nmol/L	259
Discriminators of total T < 8 nmol/L	259
Discriminators of total T < 12 nmol/L	260
DISCUSSION	261
5.2. THE ASSOCIATIONS OF TOTAL, BIOAVAILABLE AND FREE TESTOSTERONE AND SHBG WITH BODY COMPOSITION, MUSCLE STRENGTH AND PHYSICAL FUNCTION	267
SUMMARY	267
INTRODUCTION	269
MATERIALS AND METHODS	270
Participant selection	270

Measurements	270
Statistical analysis.....	270
RESULTS.....	272
Demographics.....	272
Chronic disease risk factors and behaviours.....	277
Chronic disease, surgical procedures and medications	280
Serum testosterone.....	284
Whole body lean mass	284
Abdominal fat percentage.....	284
Maximal handgrip strength	284
Physical function, role limitations and bodily pain	284
Multivariate predictive models.....	286
Whole body lean mass	286
Abdominal fat percentage.....	286
Maximal handgrip strength	291
Physical function.....	291

Limitation in usual role activities because of physical problems (Role physical).....	292
Bodily pain	292
DISCUSSION	302
5.3 ERECTILE FUNCTION & SEXUAL DESIRE: ASSOCIATIONS WITH AGE AND PLASMA TESTOSTERONE LEVELS.....	305
SUMMARY	305
INTRODUCTION.....	307
MATERIALS AND METHODS.....	309
Participant selection.....	309
Measurements	309
Statistical analyses.....	310
RESULTS.....	311
Demographics	311
Erectile function	311
Sexual desire.....	312
Chronic disease risk factors and behaviours.....	315
Erectile function	315

Sexual desire	315
Chronic disease, surgical procedures and medications	318
Erectile function	318
Sexual desire	321
Serum testosterone.....	323
Erectile function	323
Sexual desire	323
Multivariate predictive models for ED	325
Erectile dysfunction, GIR	325
Erectile function, IIEF.....	325
Multivariate predictive models for sexual desire.....	333
Sexual desire, IIEF_SD	333
Dyadic sexual desire, SDI-2.....	333
Solitary sexual desire, SDI-2.....	333
Post-hoc Chi-squared associations between obesity and erectile dysfunction.....	338
DISCUSSION	340

5.4 LOWER URINARY TRACT SYMPTOMS AND MAXIMAL URINARY FLOW RATE: RELATION TO AGE AND PLASMA TESTOSTERONE LEVELS.....	343
SUMMARY.....	343
INTRODUCTION.....	344
MATERIALS AND METHODS.....	346
Participant selection.....	346
Measurements.....	346
Statistical analyses.....	346
RESULTS.....	347
Demographics.....	347
Risk factors and behaviours.....	349
Chronic disease, surgical procedures and medications.....	349
Serum testosterone.....	353
Multivariate predictive models for LUTS and Qmax.....	353
Associations between LUTS, maximal urinary flow rate and erectile function.....	363
DISCUSSION.....	365

5.5 THE ASSOCIATIONS OF TOTAL, BIOAVAILABLE AND FREE TESTOSTERONE AND SHBG WITH NEUROPSYCHOLOGICAL FUNCTION AND MOOD.	367
SUMMARY	367
INTRODUCTION	369
MATERIALS AND METHODS.....	370
Participant selection	370
Measurements	370
Statistical analysis.....	371
RESULTS.....	372
Demographics.....	372
Chronic disease risk factors and behaviours.....	375
Chronic disease, surgical procedures and medications	377
Serum testosterone.....	380
Finger tapping, dominant hand	380
Repeated object retrieval and ineffective object reminders.....	380
TMT-B:TMT-A ratio.....	380
BDI score.....	380

Multivariate predictive models for finger tapping, memory, trail making and depression scores	383
Finger tapping.....	383
Memory: repeated object retrieval and ineffective reminders.....	383
Trail making test (TMT-B:TMT-A)	392
BDI score.....	392
DISCUSSION	397
CHAPTER 6.....	400
6.1 THE EFFECT OF 12-MONTH ORAL TESTOSTERONE UNDECANOATE (ANDRIOL®) ON BODY COMPOSITION AND MUSCLE STRENGTH IN MEN AGED 60 YEARS AND OLDER WITH LOW-NORMAL GONADAL STATUS.	400
SUMMARY	400
INTRODUCTION.....	402
METHODS	404
Participant Selection	404
Study Design:.....	405
Measurements:	405
Body composition	405

Muscle strength	405
Androgen deficiency symptoms	406
Nutrition	407
Laboratory Assays	407
Safety Monitoring	407
STATISTICAL ANALYSES:	408
RESULTS.....	409
Treatment compliance.....	409
Plasma Androgen levels	413
Body Composition.....	416
Muscle strength.....	418
Insulin Growth Factor 1	420
Safety measurements	420
DISCUSSION.....	423
6.2 THE EFFECT OF 12-MONTH ORAL TESTOSTERONE UNDECANOATE (ANDRIOL®) ON SYMPTOMS OF ANDROGEN DEFICIENCY IN MEN AGED 60 YEARS AND OLDER WITH LOW-NORMAL GONADAL STATUS.....	428

SUMMARY	428
INTRODUCTION	430
MATERIALS & METHODS	432
Participant selection	432
Study Design:	433
Measurements	433
St Louis University ADAM Questionnaire	433
Laboratory Assays	433
Calculated bioavailable testosterone (cBT)	433
Statistical analyses	434
RESULTS	435
Baseline	435
Month-12	435
DISCUSSION	440
6.3 THE EFFECT OF 12-MONTH ORAL TESTOSTERONE UNDECANOATE (ANDRIOL®) ON VISUOSPATIAL COGNITION, MOOD, WELLBEING QUALITY OF LIFE IN MEN AGED 60 YEARS AND OLDER WITH LOW-NORMAL GONADAL STATUS.	444

SUMMARY	444
INTRODUCTION	445
MATERIALS AND METHODS.....	447
Participant selection.....	447
Study Design:.....	447
Measurements	448
Trail making test part B (TMT- B).....	448
Visuospatial (VSP) block design test	448
Mini Mental State Exam (MMSE).....	449
Geriatric Depression Scale (GDS).....	449
Quality of Life (QoL) and well-being.....	449
Laboratory Assays	450
Calculated bioavailable testosterone (cBT).....	450
Statistical analyses:.....	450
RESULTS.....	451
Treatment compliance and adverse events	451

Serum Androgen levels.....	453
Visuospatial tests, mood, well-being and QoL scales	453
Post-hoc analyses.....	453
DISCUSSION.....	457
CHAPTER 7.0 THE DEVELOPMENT OF AN EMPIRICAL MEASURE OF TESTOSTERONE BIOACTION	461
SUMMARY.....	461
INTRODUCTION.....	463
MATERIALS AND METHODS.....	465
Cell lines and androgen gene regulation.....	465
Maintenance of cells.....	465
Reporter vectors	465
ARE-luc	465
ARR3-tk-luc (p(-244/-96) ₃ T81Luc).....	466
pRL-TK-Luc (Renilla luciferase)	466
Transfection protocol	466
Luciferase assay.....	467

Study plan and order of experiments	467
Experiment 1. Determination of optimal cell line.....	468
Experiment 2. Determination of optimal plating density for CHO-K1 cells	468
Experiment 3. Determination of the level of co-transfected hAR required for optimal induction of ARR3-tk-luc	468
Experiment 4. Determination of the level of ARR3-tk-luc required for optimal luciferase activity	468
Experiment 5. Determination of dose response of ARR3-tk-luc to testosterone and DHT	469
Experiment 6. Application to measurement of testosterone in human serum.....	469
Statistical analyses.....	470
RESULTS.....	471
Experiment 1. Determination of optimal cell line	471
Caco-2 cells.....	471
HeLa cells.....	471
PC3 cells	471
CHO-K1 cells.....	471
Experiment 2. Determination of optimal plating densityfor CHO-K1 cells.....	474

Experiment 3. Determination of the level of co-transfect hAR required for optimal induction of ARR3-tk-luc	476
Experiment 4. Determination of the level of ARR3-tk-luc required for optimal luciferase activity	476
Experiment 5. Determination of dose response of ARR3-tk-luc to testosterone and DHT	479
Experiment 6. Application to measurement of testosterone in human serum.....	479
DISCUSSION	482
CHAPTER 8.0 GENERAL DISCUSSION	486
REFERENCES	493

List of Tables and Figures

Figure 1.1 The effect of ageing on the negative-feedback regulation of the HPG axis.	3
Table 1.1 Cohort studies investigating androgens in ageing men.	27
Table 1.2 Cross-sectional and case-controlled studies investigating androgens in ageing men.	43
Figure 1.2. The Saint Louis University (ADAM) Questionnaire.	51
Table 1.3 Randomised controlled trials of testosterone replacement in ageing men.	68
Figure 1.3. The potential risks and benefits of testosterone treatment in ageing men.	70
Table 3.1 Age-related reference ranges for total T and cBT from 357 male Red Cross blood donors and for BT in 143 blood donors.	93
Figure 3.1 The frequency distribution of dissociation constant (K _d) values for the testosterone-SHBG complex in (a) male Red Cross blood donors aged 19-65 years and (b) men aged 60-88 with symptoms of androgen deficiency. ...	96
Table 3.2 Descriptive data from blood donor, screened symptomatic men and Andriol® trial patients.	98
Figure 3.2 The relationship between BT and cBT in (a) male Red Cross blood donors aged 19-65 years (N = 143) and (b) men aged 60-88 years with symptoms of androgen deficiency (N=131) and (c) the relationship between cBT and calculated FT in men aged 60-88 years enrolled in a clinical trial of testosterone supplementation (N=84).	99
Figure 4.1 The sampling region for the Florey Adelaide Male Ageing Study (FAMAS).	108
Table 4.1 Interpretive guidelines for the BDI.	113
Table 4.2. A log of the queries and solutions to coding anomalies.	122
Table 4.3 Power calculations for testosterone effect within an age group.	125
Figure 4.2 Participant disposition.	127
Table 4.4 Reasons for not participating in the study.	128

Table 4.5 Comparison between negative responders and study participants for age and household demographics.	131
Table 4.6 A comparison of BMI, chronic disease status and smoking between negative responders and study participants.....	133
Figure 4.3 The age distributions of the FAMAS cohort (A) and of northern and western Adelaide males between the ages of 35 and 79 years (B).....	136
Figure 4.4 Number of participants by clinic (A) and the number of men aged between 35 and 79 by residential region, from Census 2001 (B).....	137
Figure 4.5 Marital status of the cohort.....	138
Figure 4.6 A comparison of the distribution of marital status, by 5-year age group between the FAMAS cohort and 2001 Australian Census data from northern and western Adelaide.....	139
Figure 4.7 The distribution of gross annual income in the households of men aged 35 – 79 years enrolled in the FAMAS, randomly recruited from the north and west suburbs of Adelaide (panel A) and in 2001 Australian Census data from northern and western Adelaide households (panel B).....	140
Figure 4.8 A comparison of the distribution of countries of birth in the FAMAS cohort (A) and in the northern and western Adelaide male population (B).....	141
Table 4.7 The number and proportion of immigrant arrivals in Australia pre-1986 through to 2001.....	142
Figure 4.9 The proportions of men with and without post high-school qualifications (Panel A) in the FAMAS cohort and the distribution in the levels of highest post-high school qualification achieved (Panel B).....	145
Table 4.8 Highest qualifications reported in the cohort since leaving school outside of Bachelor degrees or higher, trades/apprenticeships and certificates/diplomas.....	146
Figure 4.10 The variation in work status amongst FAMAS cohort.....	147
Table 4.9 The frequency of responses given for work status other than full-time, part-time/casual, unemployed, home-duties, retired and student.....	148

Figure 4.11 The proportions of men aged 35 – 79, randomly recruited from the north and west suburbs of Adelaide, who were receiving pensions from the Department of Social Security.....	149
Table 4.10 Mean systolic and diastolic blood pressures in the overall cohort and by age group, school-leaving age, post-school qualification and annual gross household income, work status, DSS pension, marital status and country of birth.	154
Figure 4.12 The proportions of self-reported hypertensive and non-hypertensive men with high blood pressure measured at clinic and the proportion that took anti-hypertensive medication.....	155
Table 4.11 Mean body mass index and waist circumference in the overall cohort and by age group, school-leaving age, post-school qualification and annual gross household income, work status, DSS pension, marital status and country of birth.	161
Table 4.12 The proportion of current, former and non-smokers in the overall cohort and by age group, school-leaving age, post-school qualification and annual gross household income, work status, DSS pension, marital status and country of birth.	167
Table 4.13 Mean number of weekly walking, moderate intensity exercise and vigorous intensity exercise sessions in the overall cohort and by age group, school-leaving age, post-school qualification and annual gross household income, work status, DSS pension, marital status and country of birth.....	170
Table 4.14 Mean number of weekly minutes of walking, moderate intensity exercise and vigorous intensity exercise in the overall cohort and by age group, school-leaving age, post-school qualification and annual gross household income, work status, DSS pension, marital status and country of birth.....	173
Table 4.15 The proportion of men classified as sedentary, insufficiently active and sufficiently active enough to confer a health benefit in the overall cohort and by age group, school-leaving age, post-school qualification and annual gross household income, work status, DSS pension, marital status and country of birth.	176

Table 4.16 Daily intakes of energy, fat and protein in the overall cohort and by age group, school-leaving age, post-school qualification and annual gross household income, work status, DSS pension, marital status and country of birth in 568 men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide.	180
Table 4.17 Daily intakes of carbohydrate, alcohol and calcium in the overall cohort and by age group, school-leaving age, post-school qualification and annual gross household income, work status, DSS pension, marital status and country of birth in 568 men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide. .	183
Figure 4.13 The contribution of fat, carbohydrate and protein to total daily energy intake, by age group.	184
Table 4.18 A summary of physical function, general health and vitality SF-36 domain scores in the overall cohort and by age group, school-leaving age, post-school qualification and annual gross household income, work status, DSS pension, marital status and country of birth in 568 men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide.	191
Table 4.19 A summary of mental health, role physical and role emotional SF-36 domain scores in the overall cohort and by age group, school-leaving age, post-school qualification and annual gross household income, work status, DSS pension, marital status and country of birth in 568 men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide.	194
Table 4.20 A summary of social function and bodily pain SF-36 domain scores in the overall cohort and by age group, school-leaving age, post-school qualification and annual gross household income, work status, DSS pension, marital status and country of birth in 568 men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide.	197
Table 4.21 Mean serum triglyceride and total cholesterol levels in the overall cohort and by age group, school-leaving age, post-school qualification and annual gross household income, work status, DSS pension, marital status and country of birth in 568 men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide. .	202

Table 4.22 Mean serum LDL and HDL cholesterol levels in the overall cohort and by age group, school-leaving age, post-school qualification and annual gross household income, work status, DSS pension, marital status and country of birth in 568 men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide.	205
Figure 4.14 The proportions of self-reported hypercholesterolaemic and non- hypercholesterolaemic men with high total cholesterol levels measured at clinic and the proportion that took lipid-lowering medication.	206
Table 4.23 Mean serum fasting glucose and glycated haemoglobin levels in the overall cohort and by age group, school-leaving age, post-school qualification and annual gross household income, work status, DSS pension, marital status and country of birth in 568 men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide.	209
Figure 4.15 The proportions of self-reported diabetic and non-diabetic men with high HbA1c levels measured at clinic.	210
Table 4.24 The frequency of self-reported health conditions in 568 men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide.	212
Table 4.25 The frequency of “other health conditions” reported in men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide.	213
Table 4.26 The frequency of “other cancers” reported in men aged 35 – 79, randomly recruited from the north and west suburbs of Adelaide.	214
Table 4.27 The frequency of self-reported urogenital surgery in 568 men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide.	215
Table 4.28 The frequency of “other pelvic surgery” by body system, reported in men aged 35 – 79 years, randomly recruited from the north and west suburbs of Adelaide.	216
Table 4.29 The frequency of indications for medication use.	218
Table 4.30 Response rates from Australian longitudinal population-based studies.	220

Figure 5.1.1 The associations between total T, BT, cBT, FT, SHBG and age.	232
Table 5.1.1 Statistically significant age-adjusted associations between serum testosterone and SHBG levels and demographic variables	233
Table 5.1.2 Statistically significant age-adjusted associations between serum testosterone and SHBG levels and the serum levels of LH and FSH	235
Figure 5.1.2 Age-adjusted associations of serum total T with systolic blood pressure (top panel) and of serum total T and SHBG with diastolic blood pressure (bottom panel) in 568 men aged 35 – 80 years, recruited from random households in the North-west suburbs of Adelaide.	236
Figure 5.1.3 Age-adjusted associations of serum total T and SHBG (top panel), BT and cBT (middle panel) and FT (bottom panel) with waist circumference in 568 men aged 35 – 80 years, recruited from random households in the North-west suburbs of Adelaide.	237
Figure 5.1.4 Age-adjusted associations of serum total T and SHBG (top panel) and FT (bottom panel) with serum triglycerides in 568 men aged 35 – 80 years, recruited from random households in the North-west suburbs of Adelaide.	239
Figure 5.1.5 Age-adjusted associations of serum total T and SHBG with serum total cholesterol (top panel) and HDL cholesterol (bottom panel) in 568 men aged 35 – 80 years, recruited from random households in the North-west suburbs of Adelaide.....	240
Table 5.1.3 Statistically significant age-adjusted associations of serum total T, cBT and FT with daily dietary intakes of total energy, fat, carbohydrate and protein.....	241
Table 5.1.4 Statistically significant age-adjusted associations of serum testosterone and SHBG levels with fasting serum glucose, HbA1c and fasting serum insulin in.....	242
Table 5.1.5 Statistically significant age-adjusted associations of serum testosterone levels with current smoking ...	244

Figure 5.1.6 Age-adjusted associations of serum total T, BT and cBT (top panel) and FT (bottom panel) with diabetic status..... 245

Figure 5.1.7 Age-adjusted associations of serum total T and SHBG with cholesterolaemia (top panel) and the other metabolic, endocrine or nutritional health conditions (bottom panel) 246

Figure 5.1.8 Age-adjusted associations of serum BT and cBT with general health condition medication (top panel) and of BT with medication for urinary health conditions (bottom panel)..... 247

Figure 5.1.9 Age-adjusted associations of serum SHBG with angina (top panel), medication for metabolic, endocrine or nutritional health conditions (middle panel) and medication for genital conditions (bottom panel)..... 248

Table 5.1.6 A predictive model for serum total T concentration. 251

Figure 5.1.10 Regression predicted values for total T versus measured serum total T 252

Table 5.1.7 A predictive model for serum BT concentration..... 253

Figure 5.1.11 Regression predicted values for BT versus measured serum BT 254

Table 5.1.8 A predictive model for cBT concentration..... 255

Table 5.1.9 A predictive model for FT concentration..... 256

Table 5.1.10 A predictive model for SHBG concentration. 257

Figure 5.1.12 Regression predicted values for SHBG versus measured serum SHBG 258

Figure 5.2.1 Associations of lean body mass (panel A), absolute maximal handgrip strength (panel B), relative maximal handgrip strength (panel C) and abdominal fat mass (panel D) with age 274

Figure 5.2.2 Associations of Physical function (panel A), Role physical (panel B) and Bodily pain (panel C), as measured by the SF-36, and age..... 275

Table 5.2.1 Significant age-adjusted associations of lean body mass, maximal handgrip strength, physical function, role physical and bodily pain with demographic variables..... 276

Table 5.2.2 Significant age-adjusted associations of abdominal fat percentage, lean body mass, maximal handgrip strength, physical function, role physical and bodily pain with chronic disease risk factors and behaviours.....	279
Table 5.2.3 Significant age-adjusted associations of abdominal fat percentage, lean body mass, maximal handgrip strength, physical function, role physical and bodily pain with chronic disease, urogenital surgical history and medication use	283
Table 5.2.4 Significant age-adjusted associations of lean body mass, abdominal fat percentage and physical function with chronic serum testosterone and SHBG measurements.....	285
Table 5.2.5 Predictive models of serum testosterone and SHBG for lean body mass	288
Table 5.2.6 Predictive models of serum testosterone and SHBG for abdominal fat mass percentage	290
Table 5.2.7 Predictive models of serum testosterone and SHBG for maximal handgrip strength.....	294
Table 5.2.8 Predictive models of serum testosterone and SHBG for physical function.....	297
Table 5.2.9 Predictive models of serum testosterone and SHBG for limitations to usual role activities because of physical problems	299
Table 5.2.10 Predictive models of serum testosterone and SHBG for bodily pain	301
Table 5.3.1 Significant age-adjusted associations of demographics with severity of erectile dysfunction, as measured by GIR and erectile function, as measured by IIEF	312
Table 5.3.2 Significant age-adjusted associations of demographics with sexual desire, as measured by IIEF and SDI-2	314
Table 5.3.3 Significant age-adjusted associations of chronic disease risk factors with erectile dysfunction, as measured by the GIR and erectile function, as measured by IIEF	316
Table 5.3.4 Significant age-adjusted associations of chronic disease risk factors with sexual desire, as measured by the IIEF and SDI-2	317

Table 5.3.5 Significant age-adjusted associations of chronic disease, urogenital surgery and medication use with erectile dysfunction, as measured by GIR.....	319
Table 5.3.6 Significant age-adjusted associations of chronic disease, urogenital surgery and medication use with erectile function, as measured by IIEF	320
Table 5.3.7 Significant age-adjusted associations of chronic disease, urogenital surgery and medication use with sexual desire, as measured by IIEF and SDI-2.....	322
Table 5.3.8 Significant age-adjusted associations of serum testosterone concentration with sexual desire, as measured by IIEF and SDI-2.....	324
Table 5.3.9 Multivariate associations of serum testosterone and SHBG concentrations with severity of erectile dysfunction, as measured by GIR,	328
Table 5.3.10 Multivariate predictive model of erectile dysfunction severity, as measured by GIR,	329
Table 5.3.11 Multivariate associations of serum testosterone and SHBG concentrations with erectile function, as measured by IIEF,	331
Table 5.3.12 Multivariate predictive model of erectile function, as measured by IIEF,	332
Table 5.3.13 Multivariate associations of serum testosterone and SHBG concentrations with sexual desire, as measured by IIEF,	334
Table 5.3.14 Multivariate associations of serum testosterone and SHBG concentrations with dyadic sexual desire, as measured by SDI-2,	336
Table 5.3.15 Multivariate associations of serum testosterone and SHBG concentrations with solitary sexual desire, as measured by SDI-2,	337
Table 5.3.16 Chi-squared associations of waist circumference > 102 cm and BMI \geq 30 kg/m ² with presence and severity of erectile dysfunction, as measured by GIR,	339

Table 5.4.1 Significant age-adjusted associations of demographics with obstructive and irritative LUTS, as measured by IPSS and maximum urine flow rate	348
Table 5.4.2 Significant age-adjusted associations of chronic disease risk factors and behaviours with obstructive and irritative LUTS, as measured by IPSS and maximum urine flow rate	350
Table 5.4.3 Significant age-adjusted associations of chronic disease, urogenital surgical procedures and medication use with obstructive and irritative LUTS, as measured by IPSS and maximum urine flow rate	352
Table 5.4.4 Predictive models of serum testosterone and SHBG with obstructive LUTS, as measured by IPSS.....	356
Table 5.4.5 Predictive model of obstructive LUTS, as measured by IPSS.....	357
Table 5.4.6 Predictive models of serum testosterone and SHBG with irritative LUTS, as measured by IPSS.....	359
Table 5.4.7 Predictive model of irritative LUTS, as measured by IPSS.....	360
Table 5.4.8 Predictive models of serum testosterone and SHBG with Qmax	361
Table 5.4.9 Predictive model of Qmax	362
Table 5.4.10 Independent associations of erectile function with obstructive and irritative LUTS	364
Figure 5.5.1 Associations of dominant hand finger tapping (top panel) and TMT-B:TMT-A ratio (bottom panel) with age	373
Table 5.5.1 Significant age-adjusted associations of dominant hand finger tapping, repeated object retrieval, ineffective object reminders, TMT-B:TMT-A ratio and BDI score with demographic variables.....	374
Table 5.5.2 Significant age-adjusted associations of dominant hand finger tapping, repeated object retrieval, ineffective object reminders, TMT-B:TMT-A ratio and BDI score with chronic disease risk factors and behaviours ..	376
Table 5.5.3 Significant age-adjusted associations of dominant hand finger tapping, repeated object retrieval, ineffective object reminders, TMT-B:TMT-A ratio and BDI score with chronic disease, urogenital surgery and medication use	379

Figure 5.5.2 Associations of measured (top panel) and calculated (bottom panel) bioavailable testosterone with the difference in the number of ineffective object reminders between the first and the delayed recall trials of the Fuld object memory evaluation.	381
Figure 5.5.3 Associations of measured bioavailable testosterone with Beck depression inventory (BDI) score	382
Table 5.5.4 Predictive models of serum testosterone and SHBG with finger tapping on the dominant hand.....	386
Table 5.5.5 Predictive model of finger tapping on the dominant hand	387
Table 5.5.6 Predictive models of serum testosterone and SHBG with repeated object retrieval (trials 1 to delay), as measured by the Fuld object memory evaluation.....	388
Table 5.5.7 Predictive model of repeated object retrieval (trials 1 to delay), as measured by the Fuld object memory evaluation.....	389
Table 5.5.8 Predictive models of serum testosterone and SHBG with ineffective object reminders (trials 1 to delay), as measured by the Fuld object memory evaluation.....	390
Table 5.5.9 Predictive model of ineffective object reminders (trials 1 to delay), as measured by the Fuld object memory evaluation.....	391
Table 5.5.10 Predictive models of serum testosterone and SHBG with TMT-B:TMT-A ratio	393
Table 5.5.11 Predictive model of TMT-B:TMT-A ratio	394
Table 5.5.12 Predictive models of serum testosterone and SHBG with BDI score	396
Table 6.1.1 Baseline characteristics.....	411
Table 6.1.2 Details of early withdrawal.....	412
Figure 6.1.1 Plasma concentrations of total T, SHBG, FAI and cBT at baseline, 1 month, 3 months, 6 months and 12 months in Testosterone and Placebo groups.....	414

Figure 6.1.2 Plasma concentrations of LH and FSH at baseline, 3 months, 6 months and 12 months in Testosterone and Placebo groups.	415
Figure 6.1.3 Percent change from baseline in lean body mass (LBM) and body fat after 6 months and 12 months of treatment with Testosterone or Placebo.....	417
Table 6.1.3 Maximal isometric right and left grip strength and maximal concentric, isokinetic quadriceps and calf strength (dominant limb only) at baseline, month 6 and month 12 in Testosterone (T) and Placebo treated subjects.	419
Table 6.1.4 Change from baseline to month 12 for safety measures in the Testosterone and Placebo-treated groups.	422
Table 6.2.1 Mean total T and cBT levels for “yes” and “no” responses to symptoms at baseline and the percentages of positively reported ADAM symptoms at baseline (BL) and month 12 (M12), in the testosterone and placebo groups for all subjects and for those with baseline cBT < 3.1 nmol/L.....	437
Table 6.2.2 Comparison of mean total ADAM scores in all subjects and in testosterone and placebo groups, by baseline cBT.	439
Table 6.3.1 Baseline visuospatial cognition, mood and quality of life data of all subjects randomised to the Testosterone and Placebo treatment groups.	452
Table 6.3.2 Mean change from baseline to month-6 and month-12 for visuospatial tests, mood, well-being and quality of life scales in Testosterone and Placebo groups.....	455
Table 6.3.3 Visuospatial cognition, mood and quality of life scores, by baseline cBT, in Testosterone and Placebo groups at baseline, month-6 and month-12.....	456
Figure 7.0.1 The effect of Testosterone or DHT on luciferase induction of transfected ARE-luc in CaCo2 (panel A), HeLa (panel B), PC3 (panel C) and CHO-K1 (panel D) cell lines, co-transfected with varying concentrations of human androgen recepto (hAR).....	473

Figure 7.0.2 The effect of cell seeding density on ARR3-tk-luc induction in cells transfected with 400 ng of ARR3-tk-luc, co-transfected with 1ng hAR and treated with DHT (10^{-7} M) or ethanol vehicle.	475
Figure 7.0.3 The effect of co-transfection concentration of human androgen receptor (hAR) on ARR3-tk-luc induction in cells transfected with 400 ng of ARR3-tk-luc and treated with DHT (10^{-7} M) or ethanol vehicle.....	477
Figure 7.0.4 The effect of transfection concentration of ARR3-tk-luc on induction in cells co-transfected with 1 ng of hAR and treated with DHT (10^{-7} M) or ethanol vehicle.	478
Figure 7.0.5 The dose-response effect of Testosterone and DHT and suppression with Flutamide, on 400 ng ARR3-tk-luc induction in CHO-K1 cells co-transfected with 1 ng of hAR.	480
Figure 7.0.6 The effect of human male and female serum on 400 ng ARR3-tk-luc induction in CHO-K1 cells co-transfected with 1 ng of hAR.	481
Figure 8.0.1 The associations between serum testosterone, the metabolic syndrome and age-associated sarcopenia and frailty.....	492

ACKNOWLEDGEMENTS

I would like to sincerely thank:

My principal supervisor, Professor Gary Wittert for his abundant confidence and courage in allowing me to undertake such an ambitious project as the FAMAS. It was an exciting and rewarding ride. Thank you Gary, for your ever present support dating back to summer 1998-1999 and my first research project with you as a second year undergraduate. Thanks for your open door, your sharing of knowledge (even beyond the scope of my own projects) and your willingness to adapt to my needs when things got really tough. Also thank you for your efforts in all aspects of the FAMAS and Andriol trial and for the opportunity to present findings at national and international meetings.

My co-supervisors Professor Janet Hiller, Dr Peter O'Loughlin and Associate Professor Ian Chapman for their expertise, advice and encouragement. Janet, thank you for your huge influence at the many stages of study design and implementation of FAMAS. You were an integral part of the project's success. Pete, thank you for your openness and your advice on science and all things life over an ale or glass of red. Ian, thank you for your endless support, constructive criticism and level thinking (a good balance to Gary's exuberance!). Thank you for all your work on the Andriol trial that supplied me with the data for this thesis.

Janet Grant and Catherine Chittleborough for their unbelievable work ethic and willingness to teach and assist me with organizational and practical tasks and coordinating the recruitment and questionnaire mailouts for the FAMAS.

Sandy Pickering for her expertise in study clinic coordination. Thank you Sandy for your organizational skills, your unparalleled attention to detail, commitment to the task and your willingness to go out of your way to assist me in any way possible.

The other FAMAS clinic staff; Jane, Larissa, Megan and Annie. Thanks for all the hard work and commitment, for the laughs and for making the participants feel happy and at ease, your contribution to this work is very much appreciated. Dear Annie, thanks for all the little notes..... we love you Annie!

Anne Taylor, Professor Dick Ruffin and Associate Professor David Wilson for your bravery and willingness to allow us to share your clinics at TOEH and LMHS, your clinic staff and your recruitment strategies. Without your collaboration the FAMAS would not have been possible.

Giulio Comin for your assistance with the design, data collection, data entry and analysis of FAMAS data. Thank you also for your friendship and support. Congratulations on your awards from presentation of FAMAS data. All the best with your medical studies.

Sean Martin and Sue O'Connor, thanks for all your assistance with FAMAS in the latter stages of my time in Adelaide. Thanks for your friendship and your never ending support in my research and in my personal life. Your kindness will come back 10-fold. Also Laureen Graham, Helen Turnbull, Barb Parker, Natalie Luscombe-Marsh, Rosalie Vozzo, Jane Mudge, Zoe DeBlasio, Scott Clark, Michael Edmonds, Amelia Pilichiewicz, Julie Stevens, Di Gentilcore, Kate Feltrin, Tanya Little, Ixchel Brennan, Richard Chen, Renuka Visvanathan, Emma Pryzbilla, Michael Horowitz, Kristy Robertson and all at the Department of Medicine/Endocrine Unit who have been so important to my enjoyment of working in the department. I thank you all for the many ways you have helped me and supported me in my study and in the death of my Dad. My thoughts and prayers are always with you all.

Professor John Morley (St. Louis University) for sharing his unmatched knowledge of the ageing male. John it has been, and continues to be a pleasure and an honour to work with you. I thank you for the great opportunity to travel to St. Louis to complete a Post-doctoral fellowship with you. I look forward to a very productive and rewarding experience. On a more personal note, I truly thank you, Pat and your whole family for the warmth and generosity you have extended to me during my time in St. Louis.

Shylee Mackintosh for collection and analyses of strength data in the Andriol trial, reported in Chapter 6.1.

Dr Penelope Coates for collection of clinical data in the Andriol trial, reported in Chapters 6.1 – 6.3.

Dr Peter Coyle, Zanna Wurst, Catherine Doyle and Belinda Ford for your assistance in teaching me the finer points of cell culture, transient transfection and Dual-luciferase reporter assays. Professor Howard Morris whose insight led to the work towards a bioassay of testosterone action, thank you. Professor Chris Nordin whose amazing energy and knowledge led to the development of the calculated bioavailable testosterone, thank you Prof Nordin for your input and many comments on my work over the years.

IMVS, Endocrine laboratory. Thank you Judy, for your assistance with the development of the bioavailable testosterone assay. John, thank you for the many conversations and for your never ending interest in my work. Sue and Lucy, thank you for your support and assistance over the years.

The North-west Adelaide community for their support and adoption of the FAMAS ensuring its success. To all the men who continue to participate in FAMAS and who participated in the Andriol trial, thank you. This work couldn't have been done without your generous donation of time and information.

Marie-Ann Haren, Jeanette Koukourou and Sue O'Connor for assistance with the formatting and preparation of this thesis.

My many family and friends, thank you for your support and interest throughout the years. You now have something to read that explains what I have been doing for the past four years! Good luck, it might take you four years to get through it! Especially to Justin who always provided a voice of realism. Thanks for your take on the important things in life mate. To Brett, Dickie, Tim and Kim for always being there when I needed a shoulder, a laugh, a drink, another drink, a home cooked barbie or some sensational South Australian oysters! To Macca, thanks for helping me to keep the body fit mate! A fit body supports a fit mind! Thanks for the special bond of mateship we have developed over the last 9 years and particularly over the last couple of years that have been rough on both of us. Congratulations on your graduation and your new physiotherapy position in Warrnambool. To the UniSA Gaelic football club, you have been my passion over the last couple of years. I miss you all.

Finally to my wonderful Mum, sorry for the stress I have caused you by saying "It's nearly done" every time you have asked over the past 10 months. Thanks for your love and for staying strong, you are an inspiration and a blessing. I love you. Marie-Ann and Carmel, thanks for your love and support, thanks for the fun times and for trying to keep me on track...and for pulling me off track when I needed it. I love you both.

STATEMENT OF ORIGINALITY AND AUTHENTICITY

I declare that this thesis contains no material that has been accepted for the award of any other degree or diploma in any university or tertiary institution and to the best of my knowledge and belief, the thesis contains no material previously published or written by another person, except where due reference is made.

I give consent to this copy of my thesis, when deposited in the University Library, being available for loan and photocopying if accepted for the award of the degree.

Signed,

Matthew T. Haren

Date:

TABLE OF ABBREVIATIONS AND BIOCHEMICAL NAMES

ACCV	Australian Cancer Council of Victoria
ADAM	Androgen deficiency in the ageing male
AE	Adverse event
AIHW	Australian Institute of Health and Welfare
ANOVA	Analysis of variance
AR	Androgen receptor
ARCBS	Australian Red Cross Blood Service
ARE	Androgen response element
ARIP3	AR-interacting protein 3
ARR3-tk-luc	A construct containing a triple repeat of probasin ARE from rat ventral prostate
BDI	Beck depression inventory
BMD	Bone mineral density
BMI	Body mass index
BMR	Basal metabolic rate
BP	SF-36 domain: Bodily pain - intensity of bodily pain or discomfort

BPH	Benign prostatic hyperplasia
BT	Bioavailable testosterone
CaCo2	Human colon adenocarcinoma cells
cAMP	Cyclic adenosine mhey onophosphate
cBT	Calculated bioavailable testosterone
CCK	Cholecystokinin
cFT	Calculated free testosterone
CHO-K1	Chinese hamster ovary cells
CI	Confidence interval
COS-1	Kidney cells from an African green monkey
CV	Coefficient of variation
DBD	DNA binding domain
DBP	Diastolic blood pressure
DEXA	Dual energy x-ray absorptiometry
DHEA	Dehydropepiandrosterone
DHT	Dihydrotestosterone

DMEM	Dulbecco's modified Eagle's medium
DNA	Deoxyribonucleic acid
DSS	Department of Social Security
E2	Oestradiol
ED	Erectile dysfunction
ER	Oestrogen receptor
EWP	Electronic White Pages
FAI	Free androgen index
FAMAS	Florey Adelaide Male Ageing Study
FCS	Foetal calf serum
FLUT	Flutamide
FOME	Fuld object memory evaluation
fPSA	Free prostate specific antigen
FSH	Follicle stimulating hormone
FT	Free testosterone
FTT	Finger tapping test

GDS	Geriatric depression scale
GH	SF-36 domain: General health - general health perceptions
GHR	Generational Health Review
GIR	Global impotence rating
GnRH	Gonadotropin releasing hormone
hAR	Human androgen receptor
Hb	Haemoglobin
HbA1c	Glycated haemoglobin
HCG	Human chorionic gonadotropin
Hct	Haematocrit
HDL	High density lipoprotein
HeLa	Human epithelial cervix carcinoma cells
HPLC	High pressure liquid chromatography
ICC	Inter-class correlation coefficient
ICH	International Conference on Harmonisation
IGF-1	Insulin-like growth factor 1

IIEF	International index of erectile function
IMVS	Institute of Medical and Veterinary Science
IPSS	International prostate symptom scale
Kd	Dissociation constant
LBD	Ligand binding domain
LBM	Lean body mass
LDL	Low density lipoprotein
LH	Lutenising hormone
LMHS	Lyell McEwin Health Service
LUTS	Lower urinary tract symptoms
MH	SF-36 domain: Mental health - psychological distress and wellbeing
MMSE	Mini mental state examination
MNA	Mini nutritional assessment
mRNA	messenger ribonucleic acid
NaCl	Sodium chloride
OSA	Obstructive sleep apnoea

PBS	Phosphate buffered saline
PC3	Human prostate adenocarcinoma, metastatic cells from bone
PDE-5	Phosphodiesterase 5
PF	SF-36 domain: Physical function - limitations in physical activities because of health problems
PLB	Passive lysis buffer
pRL-tk	A reporter vector containing herpes simplex virus thymidine kinase promoter upstream of <i>Renilla luciferase</i>
PROS	Population Research and Outcome Studies (unit, SA Department of Human Services)
QC	Quality control
Qmax	Maximal urinary flow rate
QoL	Quality of life
QPL	Questionnaire programming language
RAH	Royal Adelaide Hospital
RE	SF-36 domain: Role emotional - limitations in usual role activities because of emotional problems
RP	SF-36 domain: Role physical - limitations in usual role activities because of physical health problems

SAE	Serious adverse event
SBP	Systolic blood pressure
SD	Standard deviation
SDI-2	Sexual desire inventory (version 2)
SE	Standard error
SF	SF-36 domain: Social functioning - limitations in social activities due to physical or emotional problems
SF-36	36-item Short form health survey
SHBG	Sex hormone binding globulin
SHBG-R	SHBG receptor
T	Testosterone
TC	Testosterone cypionate
TE	Testosterone enanthate
TMT	Trail making test
tPSA	Total prostate specific antigen
TQEH	The Queen Elizabeth Hospital
TU	Testosterone undecanoate

TURP	Trans-urethral resection of prostate
VAS	Visual analogue scale
VSP	Visuospatial (block design test)
VT	Vitality; energy and fatigue
WHO	World Health Organisation

PAPERS ARISING FROM THIS THESIS

Haren MT, Nordin BEC, Pearce CEM, O'Loughlin P, Chapman I, Morley JE, Wittert GA. The calculation of bioavailable testosterone. *Andrology in the 21st Century* [short communication]. *Proceedings of the VII International Congress of Andrology*. Robiare B, Chemis H, Morales C (eds.). 2001. Medimond: Englewood, NJ pp.209-213.

Haren MT, Morley JE, Chapman IM, O'Loughlin PD, Wittert GA. Defining 'relative' androgen deficiency in aging men: how should testosterone be measured and what are the relationships between androgen levels and physical, sexual and emotional health? *Climacteric* 5(1):15-25, 2002.

Wittert GA, Chapman IM, **Haren MT**, Mackintosh S, Coates P, Morley JE. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. *J Gerontol A Biol Sci Med Sci*. 58(7):618-25, 2003.

Haren MT, Wittert GA, Chapman IM, Coates P, Morley JE. Effect of 12-month oral testosterone undecanoate on visuospatial cognition in healthy elderly men with low-normal gonadal status. *Maturitas* 50(2):124-33.

Haren MT, Wittert GA, Chapman IM, Coates P, Morley JE. Effect of 12-month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status. *Age & Ageing* 2004 (Dec 13) Epub ahead of print.

SUMMARY

This thesis investigates the age-related decline in the various available measures and estimates of serum testosterone levels in men. Testosterone circulates predominantly bound with high affinity to sex-hormone binding globulin (SHBG) in plasma (~60%) and with lower affinity to albumin (<40%); approximately 1-2% circulates unbound in plasma. It is the albumin-bound and free fractions (termed "bioavailable testosterone") that are most likely to have biological effects on target tissues. This thesis reports the establishment, validation and derivation of normal ranges for an ammonium sulphate precipitation method for the measurement of bioavailable testosterone in serum. This method is in use by a number of laboratories at present including the laboratory of Professor John Morley at St Louis University with whom we collaborated.

Testosterone has been shown, both cross-sectionally and longitudinally, to decline progressively beginning around the age of thirty. Total testosterone declines at approximately 0.4% per year while bioavailable and free testosterone decline at approximately 1.2% per year. The mechanisms that may be responsible for this include age-related changes to the hypothalamic-pituitary-testicular axis, increased SHBG levels, environmental factors, medication and chronic illness. This decline may contribute to a multitude of physiological, psychosexual and cognitive changes associated with ageing in men. This thesis cross-sectionally examines the possible determinants of the various fractions of serum testosterone and the associations with various physical, psychosexual and lifestyle variables and with chronic disease and medication use. These cross-sectional data were generated from the Florey Adelaide Male Ageing study, which randomly recruited 568 men from the north and west suburbs of Adelaide, between August 2001 and August 2002.

Moreover, this thesis includes a randomised controlled trial of testosterone replacement therapy in men aged 60 years and over with low-normal testosterone levels at baseline, recruited by newspaper

advertisement. The goals of testosterone replacement therapy might be to prevent osteoporosis, age related frailty and falls, and to maintain optimal physical, sexual, emotional and cognitive health during the ageing process. This intervention study focused on the effect of treatment on body composition and muscle strength, symptoms of testosterone deficiency, visuospatial cognition, mood, wellbeing and quality of life.

Finally, preliminary work was initiated to develop an in vitro bioassay for the measurement of serum testosterone bio-action. This was done using a transient transfection protocol in cultured cells, where androgen receptor and androgen response elements were introduced into the cells, subsequently treated with testosterone containing media and the amplitude of response quantified using a dual-luciferase-reporter assay.

In summary, this thesis discusses the issues with the measurement of testosterone in plasma and the factors that determine the concentration of the various fractions of testosterone in plasma. A cross-sectional study, using random recruitment procedures was used to investigate associations between testosterone levels and health-related-factors and finally a randomised-controlled-trial of testosterone replacement in ageing men with low-normal testosterone levels is reported. Throughout the thesis, the following themes are common; body composition, physical function and strength, sexual function, lower urinary tract symptoms and the prostate, visuospatial cognition, mood, quality-of-life and wellbeing.